AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|
17.7 C
New York
Wednesday, September 16, 2026

Tag: PER

newssourceFORcompanyinformationcontent1releasesmarket

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. – PTCT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT).  Such...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. – NPCE

NEW YORK, June 22, 2025 /PRNewswire/ -- APomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. – RCKT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company")...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Broadmark Realty Capital Inc. of Class Action Lawsuit and Upcoming Deadlines...

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Broadmark Realty Capital Inc. ("Broadmark"...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation – DDD

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  3D Systems Corporation ("3D Systems" or the...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sable Offshore Corp. – SOC

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. ("Sable" or the "Company")...

Analyzing U.S. Household Electricity Price Increases—Strategic Implications for Stakeholders

Electricity prices are escalating rapidly for U.S. households, despite a general cooling in overall inflation. The consumer price index for May 2025 indicated a...

Kaanch Network Presale Positions Project Among Top Altcoins and Best Crypto Opportunities of 2025

DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) -- Kaanch Network’s token is set to be listed on BitMart and LBank exchanges on June 30th, an important milestone in the project’s mission to revolutionize decentralized finance and asset management. Built on a scalable and affordable Layer 1 blockchain with real-world applications, Kaanch offers developers, business owners, and investors a compelling platform for growth in 2025 and beyond.

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

1000 MIGLIA 2025, the fifth and final leg has started

Overtaken yesterday by Erejomovich-Llanos, Vesco-Salvinelli return to the lead with the first Time Trials of the day 
Overtaken yesterday by Erejomovich-Llanos, Vesco-Salvinelli return to the lead with the first Time Trials of the day

1000 MIGLIA 2025, al via la quinta ed ultima tappa

Vesco-Salvinelli, superati ieri da Erejomovich-Llanos, tornano al comando della classifica Con la prima serie di prove cronometrate di giornata 
Vesco-Salvinelli, superati ieri da Erejomovich-Llanos, tornano al comando della classifica Con la prima serie di prove cronometrate di giornata

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPER

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers